We previously reported that low expression of NPRL2 in distinct types of lung cancers was associated with cisplatin resistance (Ueda et al., 2006) and restoration of NPRL2 in NPRL2 deficient cells overcomes cisplatin resistance through the activation of the DNA damage checkpoint pathway (Jayachandran et al., 2010). Here, NPRL2 is linked to lung cancer.